Md Saiful Islam Khan
- The U.S. FDA on Thursday approved Alnylam Pharmaceuticals’ (NASDAQ:ALNY) application to add cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) to the labeling of its RNAi therapy Amvuttra (vutrisiran).
- The treatment was already approved for polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN).